Market Cap
US$49.7m
Last Updated
2019/09/16 00:10 UTC
Data Sources
Company Financials
Executive Summary
Respiri Limited, a health technology company, researches, develops, commercializes, and sells medical devices in Australia and Israel.
Snowflake
Fundamentals
Worrying balance sheet with weak fundamentals.
Risks
- Respiri has significant price volatility in the past 3 months.
- Respiri is not covered by any analysts.
Share Price & News
How has Respiri's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0%
OTCPK:KMLX.F
-0.9%
US Medical Equipment
1.3%
US Market
1 Year Return
n/a
OTCPK:KMLX.F
9.1%
US Medical Equipment
2.0%
US Market
No trading data on KMLX.F.
No trading data on KMLX.F.
Share holder returns
| KMLX.F | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | -0.9% | 1.3% |
| 30 Day | -21.3% | 0.7% | 3.9% |
| 90 Day | n/a | 4.4% | 3.4% |
| 1 Year | n/a | 10.0%9.1% | 4.2%2.0% |
| 3 Year | n/a | 70.7%65.5% | 47.2%37.6% |
| 5 Year | -41.0%-41.0% | 130.7%104.3% | 60.5%42.9% |
Price Volatility Vs. Market
How volatile is Respiri's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Respiri undervalued based on future cash flows and its price relative to the stock market?
In this section, we usually try to help investors determine whether Respiri is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Respiri has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at our analysis of KMLX.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Respiri regulatory filings here.
- Explore potentially undervalued companies in the Healthcare industry.
Future Growth
How is Respiri expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
22.6%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Respiri has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Take a look at our analysis of KMLX.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Respiri's filings and announcements here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Respiri performed over the past 5 years?
12.5%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Respiri does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
Unable to compare Respiri's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Respiri's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Respiri has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
Return on Assets
It is difficult to establish if Respiri has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Respiri improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
Next Steps
Financial Health
How is Respiri's financial position?
Financial Position Analysis
Respiri's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Respiri has no long term commitments.
Debt to Equity History and Analysis
Respiri has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
Irrelevant to check if Respiri's debt level has increased considering it has negative shareholder equity.
Balance Sheet
Low level of unsold assets.
Respiri has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Respiri has less than a year of cash runway based on current free cash flow.
Respiri has less than a year of cash runway if free cash flow continues to grow at historical rates of 28.5% each year.
Next Steps
Dividend
What is Respiri's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Respiri's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Respiri's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Respiri has not reported any payouts.
Unable to verify if Respiri's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Respiri has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Respiri's salary, the management and board of directors tenure and is there insider trading?
1.5yrs
Average management tenure
CEO
Mario Gattino 0
1.8yrs
Tenure
AU$492,832
Compensation
Mr. Mario Gattino serves as Executive Director of Respiri Limited since December 14, 2017. He has been the Chief Executive Officer at Respiri Limited since December 1, 2017. Mr. Gattino served as Country C ...
CEO Compensation Analysis
Mario's remuneration is lower than average for companies of similar size in United States of America.
Insufficient data for Mario to compare compensation growth.
Management Age and Tenure
1.5yrs
Average Tenure
The average tenure for the Respiri management team is less than 2 years, this suggests a new team.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Jan Barker
Vice-President of Business Development
- Tenure: 7.7yrs
Noam Gavriely
Medical & Scientific Advisor
- Tenure: 0yrs
- Compensation: AU$310.61k
Simon Godfrey
Medical & Scientific Advisor
- Tenure: 0yrs
Mario Gattino
CEO & Executive Director
- Tenure: 1.8yrs
- Compensation: AU$492.83k
Wani Wall
Chief Customer Experience & Communications Officer
- Tenure: 1.2yrs
Samaneh Sarraf
Chief Research Officer
- Tenure: 0yrs
Alastair Beard
Company Secretary
- Tenure: 0.5yrs
Board Members
Ross James Blair-Holt
Non-Executive Chairman
- Tenure: 0.8yrs
- Compensation: AU$11.38k
Mario Gattino
CEO & Executive Director
- Tenure: 1.8yrs
- Compensation: AU$492.83k
Bruce Thompson
Non-Executive Director and Chair of the Medical & Scientific Advisory Board
- Tenure: 0yrs
Company Information
Respiri Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Respiri Limited
- Ticker: KMLX.F
- Exchange: OTCPK
- Founded:
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$49.741m
- Listing Market Cap: AU$34.261m
- Shares outstanding: 558.88m
- Website: https://respiri.co
Location
- Respiri Limited
- 101 Collins Street
- Level 27
- Melbourne
- Victoria
- 3000
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RSH | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Nov 2006 |
| KMLX.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Nov 2006 |
| RSH | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Nov 2006 |
Biography
Respiri Limited, a health technology company, researches, develops, commercializes, and sells medical devices in Australia and Israel. The company produces and sells mobile health applications. Its product ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/16 00:10 |
| End of Day Share Price | 2019/08/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.